Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP
Brain · 02.05.2023 · 146 (5) · 2089-2106
DOI: 10.1093/brain/awac412 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 10.11.2022. Verfasst von Yuan-Ping Chu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Hauptthemen laut MEDLINE: Frontotemporal Dementia, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Ministry of Science and Technology, Taiwan, National Cheng Kung University Hospital.
Abstract (Originalsprache)
TAR DNA-binding protein-43 (TDP-43) proteinopathies are accompanied by the pathological hallmark of cytoplasmic inclusions in the neurodegenerative diseases, including frontal temporal lobar degeneration-TDP and amyotrophic lateral sclerosis. We found that transthyretin accumulates with TDP-43 cytoplasmic inclusions in frontal temporal lobar degeneration-TDP human patients and transgenic mice, in which transthyretin exhibits dramatic expression decline in elderly mice. The upregulation of transthyretin expression was demonstrated to facilitate the clearance of cytoplasmic TDP-43 inclusions through autophagy, in which transthyretin induces autophagy upregulation via ATF4. Of interest, transthyretin upregulated ATF4 expression and promoted ATF4 nuclear import, presenting physical interaction. Neuronal expression of transthyretin in frontal temporal lobar degeneration-TDP mice restored autophagy function and facilitated early soluble TDP-43 aggregates for autophagosome targeting, ameliorating neuropathology and behavioural deficits. Thus, transthyretin conducted two-way regulations by either inducing autophagy activation or escorting TDP-43 aggregates targeted autophagosomes, suggesting that transthyretin is a potential modulator therapy for neurological disorders caused by TDP-43 proteinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Pathology and Laboratory Medicine, UC Davis Medical Center, CA, USA.
- Division of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Research Center of Clinical Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
ORCID-Profile: Kuen-Jer Tsai
Förderung
- NIA NIH HHS
- Ministry of Science and Technology, Taiwan
- National Cheng Kung University Hospital
- NIH
Zitieren
APA
Chu, Y. P., Jin, L. W., Wang, L. C., Ho, P. C., Wei, W. Y., & Tsai, K. J. (2023). Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP. Brain, 146(5), 2089-2106. https://doi.org/10.1093/brain/awac412
Vancouver
Chu YP, Jin LW, Wang LC, Ho PC, Wei WY, Tsai KJ. Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP. Brain. 2023;146(5):2089-2106. doi:10.1093/brain/awac412
BibTeX
@article{Chu2023,
author = {Chu, Yuan-Ping and Jin, Lee-Way and Wang, Liang-Chao and Ho, Pei-Chuan and Wei, Wei-Yen and Tsai, Kuen-Jer},
title = {Transthyretin attenuates TDP-43 proteinopathy by autophagy activation via ATF4 in FTLD-TDP},
journal = {Brain},
year = {2023},
volume = {146},
number = {5},
pages = {2089--2106},
doi = {10.1093/brain/awac412}
}
EUVIMED